

OMHA facilitator to discuss potential settlement of claims with authorized settlement officials. Additional information on these two pilots can be found on OMHA's Web site, <http://www.hhs.gov/omha>.

In addition to these initiatives, OMHA continues to pursue new case processing efficiencies and an electronic case adjudication processing environment (ECAPE) to bring further efficiencies to the appeals process.

## II. Request for Information

OMHA is seeking input from the public on the current initiatives being undertaken at the Administrative Law Judge level, as well as suggestions for additional initiatives which could be undertaken at OMHA to address the Medicare claim and entitlement appeals workload and backlog at the Administrative Law Judge level. Input is sought on the following topics and questions:

- Are there suggestions related to the current initiatives for addressing the increased workload and/or backlog of appeals at the Administrative Law Judge level that comply with current statutory authorities and requirements?
- Are there other suggestions for addressing the increased workload and/or backlog of appeals at the Administrative Law Judge level that comply with current statutory authorities and requirements?
- Are there any current regulations that apply to the Administrative Law Judge level of the Medicare claim and entitlement appeals process that could be revised to streamline the adjudication process while ensuring that parties to the appeals, as defined at 42 CFR 405.902 and 405.906, are afforded opportunities to participate in the process and are kept apprised of appeals related to claims submitted by them or on their behalf?

(Catalog of Federal Domestic Assistance Program No. 93.770, Medicare—Prescription Drug Coverage; Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: October 30, 2014.

**Nancy J. Griswold,**

*Chief Administrative Law Judge, Office of Medicare Hearings and Appeals.*

[FR Doc. 2014–26214 Filed 11–4–14; 8:45 am]

**BILLING CODE 4150–46–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

[CFDA Number: 93.647]

#### Announcement of the Award of a Single-Source Program Expansion Supplement Grant to Child Trends, Inc., in Bethesda, MD

**AGENCY:** Office of Planning, Research and Evaluation, ACF, HHS.

**ACTION:** Announcement of the award of a single-source expansion supplement grant to Child Trends, Inc., in Bethesda, MD, to support activities that promote the economic and social well-being of individuals, families, and communities.

**SUMMARY:** The Administration for Children and Families (ACF), Office of Planning, Research and Evaluation (OPRE) announces the award of a single-source expansion supplement award in the amount of \$120,000 to Child Trends, Inc., in Bethesda, MD, to support activities that will provide research-based information to improve understanding of how to promote the economic and social well-being of underserved and under-represented populations.

**DATES:** September 30, 2014 through September 29, 2015.

**FOR FURTHER INFORMATION CONTACT:** Ann Rivera, Social Science Research Analyst, Office of Planning, Research & Evaluation, Administration for Children and Families, 370 L'Enfant Promenade SW., Washington, DC 20447; Telephone: (202) 401–5506; Email: [ann.rivera@acf.hhs.gov](mailto:ann.rivera@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under this grant program, Child Trends, Inc., a non-profit, nonpartisan research center, has established the National Research Center on Hispanic Children and Families, which brings together an interdisciplinary team of academic and organizational partners to provide leadership in culturally competent research that can inform policies concerning low-income Hispanic families and to foster significant scholarship regarding the needs and experiences of the Hispanic populations throughout the nation. This ACF-sponsored research center develops research products and research-based resources that aim to build research capacity in the field and to improve understanding of Hispanic populations in order to inform policy development and programmatic responses.

The award of a single-source expansion supplement to this research

center will support activities to develop research-based resources to inform ACF program offices, current and future ACF grantees, and potential ACF grant applicants about the characteristics and needs of underserved and under-represented populations.

**Statutory Authority:** Section 1110 of the Social Security Act (42 U.S.C. 1310).

**Melody Wayland,**

*Senior Grants Policy Specialist, Office of Administration, Office of Financial Services/ Division of Grants Policy.*

[FR Doc. 2014–26226 Filed 11–4–14; 8:45 am]

**BILLING CODE 4184–07–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2014–N–1721]

#### Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Applications

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on regulations under which the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products can be conducted.

**DATES:** Submit either electronic or written comments on the collection of information by January 5, 2015.

**ADDRESSES:** Submit electronic comments on the collection of information to <http://www.regulations.gov>. Submit written comments on the collection of information to the Division of Dockets Management (HFA 305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** FDA PRA Staff, Office of Operations, Food

and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

**Investigational New Drug (IND) Regulations—21 CFR Part 312 (OMB Control Number 0910-0014)—Extension**

FDA is requesting OMB approval for the reporting and recordkeeping requirements contained in FDA regulations entitled "Investigational New Drug Application" in 21 CFR part 312 (part 312). Part 312 implements provisions of section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) (the FD&C Act) to issue regulations under which the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products can be conducted.

FDA is charged with implementing statutory requirements that drug

products marketed in the United States be shown to be safe and effective, properly manufactured, and properly labeled for their intended uses. Section 505(a) of the FD&C Act provides that a new drug may not be introduced or delivered for introduction into interstate commerce in the United States unless FDA has previously approved a new drug application (NDA). FDA approves an NDA only if the sponsor of the application first demonstrates that the drug is safe and effective for the conditions prescribed, recommended, or suggested in the product's labeling. Proof must consist, in part, of adequate and well-controlled studies, including studies in humans, that are conducted by qualified experts. The IND regulations establish reporting requirements that include an initial application as well as amendments to that application, reports on significant revisions of clinical investigation plans, and information on a drug's safety or effectiveness. In addition, the sponsor is required to give FDA an annual summary of the previous year's clinical experience.

Submissions are reviewed by medical officers and other Agency scientific reviewers assigned responsibility for overseeing the specific study. The IND regulations also contain recordkeeping requirements that pertain to the responsibilities of sponsors and investigators. The detail and complexity of these requirements are dictated by the scientific procedures and human subject safeguards that must be followed in the clinical tests of investigational new drugs.

The IND information collection requirements provide the means by which FDA can monitor the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products, including the following: (1) Monitor the safety of ongoing clinical investigations; (2) determine whether the clinical testing of a drug should be authorized; (3) ensure production of reliable data on the metabolism and pharmacological action of the drug in humans; (4) obtain timely information on adverse reactions to the drug; (5) obtain information on side effects associated with increasing doses; (6) obtain information on the drug's effectiveness; (7) ensure the design of well-controlled, scientifically valid studies; (8) obtain other information pertinent to determining whether clinical testing should be continued, and information related to the protection of human subjects. Without the information provided by industry as required under the IND regulations, FDA cannot authorize or monitor the

clinical investigations which must be conducted prior to authorizing the sale and general use of new drugs. These reports enable FDA to monitor a study's progress, to assure subject safety, to assure that a study will be conducted ethically, and to increase the likelihood that the sponsor will conduct studies that will be useful in determining whether the drug should be marketed and available for use in medical practice.

There are two forms that are required under part 312:

Form FDA-1571—"Investigational New Drug Application." A person who intends to conduct a clinical investigation submits this form to FDA. It includes the following information: (1) A cover sheet containing background information on the sponsor and investigator; (2) a table of contents; (3) an introductory statement and general investigational plan; (4) an investigator's brochure describing the drug substance; (5) a protocol for each planned study; (6) chemistry, manufacturing, and control information for each investigation; (7) pharmacology and toxicology information for each investigation; and (8) previous human experience with the investigational drug.

Form FDA-1572—"Investigator Statement." Before permitting an investigator to begin participation in an investigation, the sponsor must obtain and record this form. It includes background information on the investigator and the investigation, and a general outline of the planned investigation and the study protocol.

FDA is requesting OMB approval for the following reporting and recordkeeping requirements in part 312.

**I. Reporting Requirements**

- 21 CFR 312.2(e)—Requests for FDA advice on the applicability of part 312 to a planned clinical investigation.
- 21 CFR 312.6—Labeling of an investigational new drug. Estimates for the information collection in this requirement are included under § 312.23(a)(7)(iv)(d).
- 21 CFR 312.8—Charging for investigational drugs under an IND.
- 21 CFR 312.10—Applications for waiver of requirements under part 312. As indicated in § 312.10(a), estimates for the information collection in this requirement are included under §§ 312.23 and 312.31. In addition, other waiver requests under § 312.10 are estimated in table 1.
- 21 CFR 312.20(c)—Applications for investigations involving an exception from informed consent under § 50.24 (21 CFR 50.24). Estimates for the

- information collection in this requirement are included under § 312.23.
- 21 CFR 312.23—IND (content and format).
- .23(a)(1)—Cover sheet FDA-1571.
- .23(a)(2)—Table of Contents.
- .23(a)(3)—Investigational plan for each planned study.
- .23(a)(5)—Investigator's brochure.
- .23(a)(6)—Protocols—Phase 1, 2, and 3.
- .23(a)(7)—Chemistry, manufacturing, and control information.
- .23(a)(7)(iv)(a),(b),(c)—A description of the drug substance, a list of all components, and any placebo used.
- .23(a)(7)(iv)(d)—Labeling: Copies of labels and labeling to be provided each investigator.
- .23(a)(7)(iv)(e)—Environmental impact analysis regarding drug manufacturing and use.
- .23(a)(8)—Pharmacological and toxicology information.
- .23(a)(9)—Previous human experience with the investigational drug.
- .23(a)(10)—Additional information.
- .23(a)(11)—Relevant information.
- .23(f)—Identification of exception from informed consent.
- 21 CFR 312.30—Protocol amendments.
- .30(a)—New protocol
- .30(b)—Changes in protocol
- .30(c)—New investigator.
- .30(d)—Content and format.
- .30(e)—Frequency.
- 21 CFR 312.31—Information amendments.
- .31(b)—Content and format.—Chemistry, toxicology, or technical information.
- 21 CFR 312.32—Safety reports.
- .32(c)(1)—Written reports to FDA and to investigators.
- .32(c)(2)—Telephone reports to FDA for fatal or life-threatening experience.
- .32(c)(3)—Format or frequency.
- .32(d)—Followup submissions.
- 21 CFR 312.33—Annual reports.
- .33(a)—Individual study information.
- .33(b)—Summary information.
- (b)(1)—Adverse experiences.
- (b)(2)—Safety report summary.
- (b)(3)—List of fatalities and causes of death.
- (b)(4)—List of discontinuing subjects.
- (b)(5)—Drug action.
- (b)(6)—Preclinical studies and findings.
- (b)(7)—Significant changes.
- .33(c)—Next year general investigational plan.
- .33(d)—Brochure revision.
- .33(e)—Phase I protocol modifications.
- .33(f)—Foreign marketing developments.
- 21 CFR 312.38(b) and (c)—Notification of withdrawal of an IND.
- 21 CFR 312.41—Comment and advice on an IND. Estimates for the information collection in this requirement are included under § 312.23.
- 21 CFR 312.42—Sponsor requests that a clinical hold be removed, and submits a complete response to the issues identified in the clinical hold order.
- 21 CFR 312.44(c) and (d)—Opportunity for sponsor response to FDA when IND is terminated.
- 21 CFR 312.45(a) and (b)—Sponsor request for, or response to, an inactive status determination of an IND.
- 21 CFR 312.47—Meetings, including “End-of-Phase 2” meetings and “Pre-NDA” meetings.
- 21 CFR 312.48—Dispute resolution. Estimates for the information collection in this requirement are included under § 312.47.
- 21 CFR 312.53(c)—Investigator information. Investigator report (Form FDA-1572) and narrative; Investigator's background information; Phase 1 outline of planned investigation and Phase 2 outline of study protocol.
- 21 CFR 312.54(a) and (b)—Sponsor submissions concerning investigations involving an exception from informed consent under § 50.24.
- 21 CFR 312.55(b)—Sponsor reports to investigators on new observations, especially adverse reactions and safe use. Only “new observations” are estimated under this section; investigator brochures are included under § 312.23.
- 21 CFR 312.56(b), (c), and (d)—Sponsor monitoring of all clinical investigations, investigators, and drug safety; notification to FDA and others.
- 21 CFR 312.58(a)—Sponsor's submission of records to FDA on request.
- 21 CFR 312.64—Investigator reports to the sponsor.
- .64(a)—Progress reports.
- .64(b)—Safety reports
- .64(c)—Final reports.
- .64(d)—Financial disclosure reports.
- 21 CFR 312.66—Investigator reports to institutional review board (IRB). Estimates for the information collection in this requirement are included under § 312.53.
- 21 CFR 312.70—Investigator disqualification; opportunity to respond to FDA.
- 21 CFR 312.83—Sponsor submission of treatment protocol. Estimates for this requirement are included under § 312.320.
- 21 CFR 312.85—Sponsors conducting phase 4 studies. Estimates for the information collection in this requirement are included under § 312.23, and under §§ 314.50, 314.70, and 314.81 in OMB control number 0910-0001.
- 21 CFR 312.110(b)—Requests to export an investigational drug.
- 21 CFR 312.120—Submissions related to foreign clinical studies not conducted under an IND.
- 21 CFR 312.130—Requests for disclosable information in an IND and from investigations involving an exception from informed consent under § 50.24.
- 21 CFR 312.310(b); 312.305(b)—Submissions related to expanded access and treatment of an individual patient.
- 21 CFR 312.310(d)—Submissions related to emergency use of an investigational new drug.
- 21 CFR 312.315(c); 312.305(b)—Submissions related to expanded access and treatment of an intermediate-size patient population.
- 21 CFR 312.320—Submissions related to a treatment IND or treatment protocol.

## II. Recordkeeping Requirements

- 21 CFR 312.52(a)—Transfer of obligations to a contract research organization.
- 21 CFR 312.57—Sponsor recordkeeping on the investigational drug.
- 21 CFR 312.59—Sponsor recordkeeping of disposition of unused supply of drugs. Estimates for the information collection in this requirement are included under § 312.57.
- 21 CFR 312.62(a)—Investigator recordkeeping of disposition of drugs.
- 21 CFR 312.62(b)—Investigator recordkeeping of case histories of individuals.
- 21 CFR 312.120(d)—Recordkeeping requirements for submissions related to foreign clinical studies not conducted under an IND. Estimates for the information collection in this requirement are included under § 312.57.
- 21 CFR 312.160(a)(3)—Records pertaining to the shipment of drugs for investigational use in laboratory research animals or in vitro tests.
- 21 CFR 312.160(c)—Shipper records of alternative disposition of unused drugs.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN FOR HUMAN DRUGS<sup>1</sup>

21 CFR Section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
312.2(e), Requests for FDA advice on the applicability of part 312 to a planned clinical investigation .....	800	1	800	24	19,200
312.8, Requests to charge for an investigational drug .....	56	1.25	70	48	3,360
312.10, Requests to waive a requirement in part 312 .....	50	1.76	88	24	2,112
312.23(a) through (f), IND content and format (including Form FDA 1571) .....	1,689	1.57	2,648	1,600	4,236,800
312.30(a) through (e), Protocol amendments .....	3,739	5.77	21,588	284	6,130,992
312.31(b), Information amendments .....	4,537	3.39	15,377	100	1,537,700
312.32(c) and (d), IND Safety reports .....	755	24.28	18,332	32	586,624
312.33(a) through (f), IND Annual reports .....	2,877	2.76	7,953	360	2,863,080
312.38(b) and (c), Notifications of withdrawal of an IND ..	862	1.54	1,328	28	37,184
312.42, Sponsor requests that a clinical hold be removed, including sponsor submission of a complete response to the issues identified in the clinical hold order .....	158	1.30	205	284	58,220
312.44(c) and (d), Sponsor responses to FDA when IND is terminated .....	12	1	12	16	192
312.45(a) and (b), Sponsor requests for or responses to an inactive status determination of an IND by FDA .....	260	1.73	451	12	5,412
312.47, Meetings, including “End-of-Phase 2” meetings and “Pre-NDA” meetings .....	225	1.86	419	160	67,040
312.53(c), Investigator reports submitted to the sponsor, including Form FDA 1572, curriculum vitae, clinical protocol, and financial disclosure. (Third party disclosure) .....	1,444	8.38	12,087	80	966,960
312.54(a), Sponsor submissions to FDA concerning investigations involving an exception from informed consent under 21 CFR 50.24 .....	7	5	35	48	1,680
312.54(b), Sponsor notifications to FDA and others concerning an IRB determination that it cannot approve research because it does not meet the criteria in the exception from informed consent in § 50.24(a). (Includes third party disclosure) .....	7	1	7	48	336
312.55(a), Investigator brochures submitted by the sponsor to each investigator. (Third party disclosure) .....	590	3.50	2,067	48	99,216
312.55(b), Sponsor reports to investigators on new observations, especially adverse reactions and safe use. (Third party disclosure) .....	590	3.50	2,067	48	99,216
312.56(b), (c), and (d), Sponsor notifications to FDA and others resulting from: (1) The sponsor’s monitoring of all clinical investigations and determining that an investigator is not in compliance with the investigation agreements; (2) the sponsor’s review and evaluation of the evidence relating to the safety and effectiveness of the investigational drug; and (3) the sponsor’s determination that the investigational drug presents an unreasonable and significant risk to subjects. (Includes third party disclosure) .....	3,584	6.52	23,355	80	1,868,400
312.58(a), Sponsor’s submissions of clinical investigation records to FDA on request during FDA inspections .....	60	1	60	8	480
312.64, Investigator reports to the sponsor, including progress reports, safety reports, final reports, and financial disclosure reports. (Third party disclosure) .....	1,444	1	1,444	24	34,656
312.70, During the disqualification process of a clinical investigator by FDA, the number of investigator responses or requests to FDA following FDA’s notification to an investigator of its failure to comply with investigation requirements .....	4	1	4	40	160
312.110(b)(4) and (b)(5), Written certifications and written statements submitted to FDA relating to the export of an investigational drug .....	11	26.28	289	75	21,675
312.120(b), Submissions to FDA of “supporting information” related to the use of foreign clinical studies not conducted under an IND .....	1,414	8.63	12,198	32	390,336
312.120(c), Waiver requests submitted to FDA related to the use of foreign clinical studies not conducted under an IND .....	35	2.34	82	24	1,968
312.130, Requests for disclosable information in an IND and for investigations involving an exception from informed consent under § 50.24 .....	3	1	3	8	24

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN FOR HUMAN DRUGS<sup>1</sup>—Continued

21 CFR Section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
312.310(b) and 312.305(b), Submissions related to expanded access and treatment of an individual patient ..	228	1.76	401	8	3,208
312.310(d), Submissions related to emergency use of an investigational new drug .....	410	2.19	899	16	14,384
312.315(c) and 312.305(b), Submissions related to expanded access and treatment of an intermediate-size patient population .....	44	7.07	311	120	37,320
312.320(b), Submissions related to a treatment IND or treatment protocol .....	12	12.67	152	300	45,600
Total .....					19,134,039

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN FOR HUMAN DRUGS<sup>1</sup>

21 CFR Section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per record-keeping	Total hours
312.52(a), Sponsor records for the transfer of obligations to a contract research organization.	335	1.50	503	2 .....	1,006
312.57, Sponsor recordkeeping showing the receipt, shipment, or other disposition of the investigational drug, and any financial interests.	1,689	1	1,689	100 .....	168,900
312.62(a), Investigator recordkeeping of the disposition of drugs.	1,444	1	1,444	40 .....	57,760
312.62(b), Investigator recordkeeping of case histories of individuals.	1,444	1	1,444	40 .....	57,760
312.160(a)(3), Records pertaining to the shipment of drugs for investigational use in laboratory research animals or in vitro tests.	547	1.40	782	0.50 (30 minutes).	391
312.160(c) Shipper records of alternative disposition of unused drugs.	547	1.40	782	0.50 (30 minutes).	391
Total .....					286,190

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

TABLE 3—ESTIMATED ANNUAL REPORTING BURDEN FOR BIOLOGICS<sup>1</sup>

21 CFR section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
312.2(e), Requests for FDA advice on the applicability of part 312 to a planned clinical investigation .....	217	1.18	255	24	6,120
312.8, Requests to charge for an investigational drug .....	20	1.50	30	48	1,440
312.10, Requests to waive a requirement in part 312 .....	2	1	2	24	48
312.23(a) through (f), IND content and format .....	335	1.35	452	1,600	723,200
312.30(a) through (e), Protocol amendments .....	694	5.84	4,050	284	1,150,200
312.31(b), Information amendments .....	77	2.43	187	100	18,700
312.32(c) and (d), IND Safety reports .....	161	8.83	1,421	32	45,472
312.33(a) through (f), IND Annual reports .....	745	2.14	1,595	360	574,200
312.38(b) and (c), Notifications of withdrawal of an IND ..	134	1.69	227	28	6,356
312.42, Sponsor requests that a clinical hold be removed, including sponsor submission of a complete response to the issues identified in the clinical hold order	67	1.30	87	284	24,708
312.44(c) and (d), Sponsor responses to FDA when IND is terminated .....	34	1.15	39	16	624
312.45(a) and (b), Sponsor requests for or responses to an inactive status determination of an IND by FDA .....	55	1.38	76	12	912
312.47, Meetings, including "End-of-Phase 2" meetings and "Pre-NDA" meetings .....	88	1.75	154	160	24,640
312.53(c), Investigator reports submitted to the sponsor, including Form FDA-1572, curriculum vitae, clinical protocol, and financial disclosure .....	453	6.33	2,869	80	229,520

TABLE 3—ESTIMATED ANNUAL REPORTING BURDEN FOR BIOLOGICS<sup>1</sup>—Continued

21 CFR section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
312.54(a), Sponsor submissions to FDA concerning investigations involving an exception from informed consent under § 50.24 .....	1	1	1	48	48
312.54(b), Sponsor notifications to FDA and others concerning an IRB determination that it cannot approve research because it does not meet the criteria in the exception from informed consent in § 50.24(a) .....	1	1	1	48	48
312.55(a), Number of investigator brochures submitted by the sponsor to each investigator .....	239	1.91	457	48	21,936
312.55(b), Number of sponsor reports to investigators on new observations, especially adverse reactions and safe use .....	243	4.95	1,203	48	57,744
312.56(b), (c), and (d), Sponsor notifications to FDA and others resulting from: (1) The sponsor's monitoring of all clinical investigations and determining that an investigator is not in compliance with the investigation agreements; (2) the sponsor's review and evaluation of the evidence relating to the safety and effectiveness of the investigational drug; and (3) the sponsor's determination that the investigational drug presents an unreasonable and significant risk to subjects .....	108	2.21	239	80	19,120
312.58(a), Number of sponsor's submissions of clinical investigation records to FDA on request during FDA inspections .....	7	1	7	8	56
312.64, Number of investigator reports to the sponsor, including progress reports, safety reports, final reports, and financial disclosure reports .....	2,728	3.82	10,411	24	249,864
312.70, During the disqualification process of a clinical investigator by FDA, the number of investigator responses or requests to FDA following FDA's notification to an investigator of its failure to comply with investigation requirements .....	5	1	5	40	200
312.110(b)(4) and (b)(5), Number of written certifications and written statements submitted to FDA relating to the export of an investigational drug .....	18	1	18	75	1,350
312.120(b), Number of submissions to FDA of "supporting information" related to the use of foreign clinical studies not conducted under an IND .....	280	9.82	2,750	32	88,000
312.120(c), Number of waiver requests submitted to FDA related to the use of foreign clinical studies not conducted under an IND .....	7	2.29	16	24	384
312.130, Number of requests for disclosable information in an IND and for investigations involving an exception from informed consent under § 50.24 .....	350	1.34	470	8	3,760
312.310(b) and 312.305(b), Number of submissions related to expanded access and treatment of an individual patient .....	78	1.08	84	8	672
312.310(d), Number of submissions related to emergency use of an investigational new drug .....	76	2.76	210	16	3,360
312.315(c) and 312.305(b), Number of submissions related to expanded access and treatment of an intermediate-size patient population .....	9	1	9	120	1,080
312.320(b), Number of submissions related to a treatment IND or treatment protocol .....	1	1	1	300	300
Total .....					3,254,062

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

TABLE 4—ESTIMATED ANNUAL RECORDKEEPING BURDEN FOR BIOLOGICS<sup>1</sup>

21 CFR Section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per record-keeping	Total hours
312.52(a), Sponsor records for the transfer of obligations to a contract research organization.	75	1.40	105	2 .....	210

TABLE 4—ESTIMATED ANNUAL RECORDKEEPING BURDEN FOR BIOLOGICS<sup>1</sup>—Continued

21 CFR Section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per record-keeping	Total hours
312.57, Sponsor recordkeeping showing the receipt, shipment, or other disposition of the investigational drug, and any financial interests.	335	2.70	904	100 .....	90,400
312.62(a), Investigator recordkeeping of the disposition of drugs.	453	1	453	40 .....	18,120
312.62(b), Investigator recordkeeping of case histories of individuals.	453	1	453	40 .....	18,120
312.160(a)(3), Records pertaining to the shipment of drugs for investigational use in laboratory research animals or in vitro tests.	111	1.40	155	0.50 (30 minutes).	78
312.160(c), Shipper records of alternative disposition of unused drugs.	111	1.40	155	0.50 (30 minutes).	78
Total .....	.....	.....	.....	.....	127,006

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: October 31, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014–26304 Filed 11–4–14; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2013–N–1119]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Canning Establishment Registration, Process Filing, and Recordkeeping for Acidified Foods and Thermally Processed Low-Acid Foods in Hermetically Sealed Containers; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA or we) is correcting a notice that appeared in the *Federal Register* of August 14, 2014. The notice announced that a proposed collection of information had been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. In this document, we correct some errors that appeared in the notice.

**FOR FURTHER INFORMATION CONTACT:** FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE–14526, Silver Spring, MD 20993–0002, *PRAStaff@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** In FR Doc. 2014–19241, appearing on page 47642 in the *Federal Register* of August 14, 2014 (79 FR 47642), we make the following corrections:

1. On page 47643, in the second column, in the Response to Comment 3, delete the sentence starting with “The scope of the voluntary submission . . . and the product label.”

2. On page 47643, in the second column, in the Response to Comment 3, in the sentence starting with “Consequently, we have proposed . . .” delete “institute the voluntary consultation process discussed in this document” and replace it with “provide for the voluntary registration and Form FDA 2541e submission process”.

3. On page 47643, in the second and third columns, in the Response to Comment 3, delete the sentences starting with “The ability to submit a voluntary submission . . . of part 114” and the remaining sentences in the response and replace them with “FDA has authority to implement the voluntary submission process under sections 402 and 404 of the FD&C Act.”

4. On page 47643, in the third column, in the Response to Comment 4, replace the response with the following: “A voluntary process filing submission will not result in part 114 applying to products that are not acidified foods as defined in 21 CFR 114.3(b). Further, the voluntary process filing submission process will not result in any changes to part 114.”

5. On pages 47643 to 47644, in the third column on page 47643 and in the first column on page 47644, in the Response to Comment 5, replace the response with the following: “Our inspectors will not expect all

manufacturers to submit voluntary submissions.”

6. On page 47644, in the first column, in the Response to Comment 7, replace the response with the following: “As discussed in the response to Comment 4, if a product is not an acidified food, the product is not subject to the good manufacturing practice requirements in part 114 and will not become subject to those regulations as a result of a voluntary submission.”

7. On page 47644, in the first and second columns, in the Response to Comment 8, replace the response with the following: “The draft guidance did address the issue of what constitutes a fermented food. We expect that the acidified foods guidance, when finalized, will provide guidance on what constitutes a fermented food.”

8. On page 47644, in the second column, in the Response to Comment 9, replace the response with the following: “Manufacturers are free to decide whether to make a voluntary submission, and we believe that some manufacturers may choose to do so. For FDA, the voluntary submission results in increased efficiency.”

9. On page 47644, in the second and third columns, in the Response to Comment 10, delete the first paragraph of the response and delete the second sentence in the second paragraph of the response.

10. On page 47645, in the first column, in the Response to Comment 13, in the second sentence in the second paragraph of the response, delete “to prevent the detention of product”.

11. On page 47645, in the third column, in the Response to Comment 20, in the first sentence of the response, replace “and provides” with “and, when finalized, will provide”.